Dr Aziz Mustafa recently joined biomodal as our Director of Sales and Business Development for Europe.
We caught up with Aziz to learn more about him, his background, and what excites him about the field of epigenetics.
Two decades ago the Human Genome Project was completed. Since then, the first sequence of the human genome and subsequent population genomes have provided critical
There is more to DNA than the genetic alphabet A, C, G and T. Epigenetics plays a causal role in cell fate, ageing and disease development.
In a recent paper published in Cell, researchers from Harvard Medical School investigated if loss of epigenetic information was a cause of ageing. To do
In this article, we highlight three recent studies that showcase the power of methylation screening for the diagnosis and prognostic measurement of different types of
Learn how simultaneous measurement of genetics and epigenetics with duet multiomics solution +modC enables the study of allele-specific methylation and how this can be used to understand the impact of epigenetic rejuvenation.
Review performance of duet multiomics solution +modC for the detection of genetic and epigenetic sequence data at base resolution when using formalin damaged DNA. Samples include formalin-compromised DNA standards (fcDNA) as well as DNA extracted from formalin-fixed and paraffin-embedded (FFPE) samples of two colorectal cancer (CRC) patients.
Learn how duet multiomics solution +modC is transforming research efforts in early cancer detection, risk stratification, and disease monitoring by using liquid biopsy for profiling of cfDNA. This poster illustrates how capturing complete genetic and epigenetic information in one workflow, from a single low-volume DNA sample is more powerful for early disease detection than either alone.
biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single
It all started with an epigenetic discovery Since Cambridge Epigenetix began in 2012, we’ve been innovating in the field of DNA sequencing and epigenetics. Back
